Patient Leaflet Updated 24-Aug-2022 | Novo Nordisk Limited
NovoSeven 1 mg (50 KIU) , NovoSeven 2 mg (100 KIU) , NovoSeven 5 mg (250 KIU) , NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection
NovoSeven®
1 mg (50 KIU)
2 mg (100 KIU)
5 mg (250 KIU)
8 mg (400 KIU)
powder and solvent for solution for injection
eptacog alfa (activated)
1. What NovoSeven® is and what it is used for
2. What you need to know before you use NovoSeven®
3. How to use NovoSeven®
4. Possible side effects
5. How to store NovoSeven®
6. Contents of the pack and other information
Overleaf: Instructions on how to use NovoSeven®
NovoSeven® is a blood coagulation factor. It works by making the blood clot at the site of bleeding, when the body's own clotting factors are not working.
NovoSeven® is used to treat bleeding, and to prevent excessive bleeding after surgery or other important treatments. Early treatment with NovoSeven® reduces how much you bleed and for how long. It works in all types of bleeds, including joint bleeds. This reduces the need for hospitalisation and days absent from work and school.
It is used in certain groups of people:
NovoSeven can also be given to you by a doctor to treat heavy bleeding after delivery of your baby, even if you do not have a bleeding disorder.
Before treatment with NovoSeven®, make sure your doctor knows:
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not use NovoSeven® at the same time as prothrombin complex concentrates or rFXIII. You should talk to your doctor before using NovoSeven® if you also use Factor VIII or IX products.
There is limited experience of using NovoSeven® together with medicines called antifibrinolytic drugs (such as aminocaproic acid or tranexamic acid) which are also used to control bleeding. You should talk to your doctor before using NovoSeven® with these medicines.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you use NovoSeven®.
There are no studies on the effect of NovoSeven® on the ability to drive and use machines. However, there is no medical reason to think that it would affect your ability.
This medicine contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially ‘sodium-free’.
The NovoSeven® powder must be reconstituted with its solvent and injected into a vein. See overleaf for detailed instructions.
Start treatment of a bleed as early as possible, ideally within 2 hours.
Do not treat yourself for longer than 24 hours without consulting your doctor.
The first dose should be given as early as possible after bleeding has started. Talk to your doctor about when to use the injections and how long to keep using them.
The dose will be worked out by your doctor, based on your body weight, condition and type of bleed.
To achieve the best results, follow the prescribed dose carefully. Your doctor might change the dose.
If you have haemophilia:
The usual dose is 90 micrograms for every 1 kilogram you weigh; you can repeat the injection every 2–3 hours until bleeding is controlled.
Your doctor may recommend a single dose of 270 micrograms for every 1 kilogram you weigh. There is no clinical experience in people over 65 using this single dose.
If you have Factor VII deficiency:
The usual dose range is 15 to 30 micrograms for every 1 kilogram you weigh, for each injection.
If you have Glanzmann’s thrombasthenia:
The usual dose is 90 micrograms (range is 80 to 120 micrograms) for every 1 kilogram you weigh, for each injection.
If you inject too much NovoSeven®, get medical advice at once.
If you forget an injection, or if you want to stop the treatment, get your doctor's advice.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Rare (may affect up to 1 in 1,000 treatment episodes)
Uncommon (may affect up to 1 in 100 treatment episodes)
Remind your doctor if you have a history of allergic reactions as you may need to be monitored more carefully. In most cases of blood clots, the patients were predisposed to blood clotting disorders.
(may affect up to 1 in 1,000 treatment episodes)
(may affect up to 1 in 100 treatment episodes)
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects you can help provide more information on the safety of this medicine.
The powder for solution for injection contains: 1 mg/vial (corresponding to 50 KIU/vial), 2 mg/vial (corresponding to 100 KIU/vial), 5 mg/vial (corresponding to 250 KIU/vial) or 8 mg/vial (corresponding to 400 KIU/vial).
After reconstitution, 1 ml of the solution contains 1 mg eptacog alfa (activated).
1 KIU equals 1,000 IU (International Units).
The powder vial contains white powder and the pre-filled syringe contains a clear colourless solution. The reconstituted solution is colourless. Do not use the reconstituted solution if you notice particles in it or if it is discoloured.
Each NovoSeven® pack contains:
Pack sizes: 1 mg (50 KIU), 2 mg (100 KIU), 5 mg (250 KIU) and 8 mg (400 KIU).
Please refer to outer packaging for present pack size.
This leaflet was last revised in 04/2022
NovoSeven® is a trademark owned by Novo Nordisk Health Care AG, Switzerland
© 2022
Novo Nordisk A/S
NovoSeven® is supplied as a powder. Before injection (administration) it must be reconstituted with the solvent supplied in the syringe. The solvent is a histidine solution. The reconstituted NovoSeven® must be injected into your vein (intravenous injection). The equipment in this package is designed to reconstitute and inject NovoSeven®.
You will also need an administration set (tubing and butterfly needle, sterile alcohol swabs, gauze pads and plasters). These devices are not included in the NovoSeven® package.
Do not use the equipment without proper training from your doctor or nurse.
Always wash your hands and ensure that the area around you is clean.
When you prepare and inject medication directly into the vein, it is important to use a clean and germ free (aseptic) technique. Improper technique can introduce germs that can infect the blood.
Do not open the equipment until you are ready to use it.
Do not use the equipment if it has been dropped, or if it is damaged. Use a new package instead.
Do not use the equipment if it is expired. Use a new package instead. The expiry date is printed after ‘EXP’ on the outer carton, on the vial, on the vial adapter and on the pre-filled syringe.
Do not use the equipment if you suspect it is contaminated. Use a new package instead.
Do not dispose of any of the items until after you have injected the reconstituted solution.
The equipment is for single use only.
The package contains:
Use the reconstituted NovoSeven® at once to avoid infections.
If you cannot use it at once, see section 5 How to store NovoSeven® on the other side of this leaflet. Do not store the reconstituted solution without advice from your doctor or nurse.
(I)
If your dose requires more than one vial, repeat steps A to J with additional vials, vial adapters and pre-filled syringes until you have reached your required dose.
Injecting NovoSeven® with pre-filled syringe via needleless connectors for intravenous (IV) catheters
Caution: The pre-filled syringe is made of glass and is designed to be compatible with standard luer-lock connections. Some needleless connectors with an internal spike are incompatible with the pre-filled syringe. This incompatibility may prevent administration of the drug and/or result in damage to the needleless connector.
Follow the instructions for use for the needleless connector. Administration through a needleless connector may require withdrawal of the reconstituted solution into a standard 10 ml sterile luer-lock plastic syringe. This should be done right after step J.
NovoSeven® is now ready to inject into your vein.
Injecting the solution via a central venous access device (CVAD) such as a central venous catheter or a subcutaneous port:
Do not disassemble the equipment before disposal.
Do not reuse the equipment.
3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA
+44 (0)1293 613535
+44 (0)800 023 2573
http://www.novonordisk.co.uk
+44 (0)1293 613555
+44 (0)800 023 2573